🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The 19th St. Gallen Conference took place this week in Vienna. Nearly 80 expert panelists voted on key debated topics in breast oncology, selected by Harold J. Burstein, MD, PhD, FASCO & G Curigliano MD PhD. Here’s 10 key results from the #SGBCC2025 consensus voting, divided by topic/breast cancer subtype.

A 30-year study of 100K+ people found that plant-forward diets with fruits, veggies, whole grains, nuts, and healthy fats boost the odds of aging well—physically, mentally, and cognitively. Avoiding processed foods and red meats matters. nature.com/articles/s4159…

Given the supposed mechanism of action of ADCs, it originally seemed logical that resistance would derive from the mAb target. The evidence, however, is proving this theory wrong. Tumors become largely resistant to the chemo payload.

Attend innovative sessions to explore how medical advancements can promote equity in #CancerCare at #SCHD25, Apr 25-27 in #Seattle: buff.ly/spFI20L 💡Join our Annual Gala for building the cancer hospital in #Nepal: buff.ly/2MAiwIH 🔖Read more:

Multiplex Spatial Proteomic Analysis of HER2–Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response | JCO Precision Oncology ascopubs.org/doi/abs/10.120… Very provocative study to identify HER2-dependance and de-escalate NACT

Our latest research published in Gynecologic Oncology: We have created a novel biomarker called ECPPF (E2F1 + CCNA2 expression + POLE, PPP2R1A, and FBXW7 mutations), which helped identified a subset of patients with traditionally low-risk endometrioid endometrial cancer who

Final #SOLO3 results: Olaparib improved ORR & PFS vs nonplatinum chemo in BRCA-mut PSR ovarian ca, but no OS benefit (HR 1.07; p=0.71). Better OS with 2 prior lines (HR 0.83), worse with ≥3 (HR 1.33). BRCA reversion mutations may explain. #PARPi OncoAlert OncoDaily

A lot is happening in breast cancer! ASCENT-04 reports improvement in PFS for sacituzumab + pembro vs TPC+pembro in 1L mTNBC, & DESTINY-Breast09 reports improved PFS for TDXd+P vs THP in 1L metastatic HER2+ breast cancer! Nice to see new options for our pts!

Mind expanding session on #ImplementationScience at #SCHD25! Dr. Lifang Hou's presentation on cancer prevention in global settings, with panel insights from Salene M. W. Jones, PhD; Katrina Ortblad, ScD, MPH, and session chairs Sid Yadav MD, FACP & Catherine Duggan, PhD, illustrated the

Excited to share our new publication led by Allison Kurian and Dr. Fergus Couch, exploring how established breast cancer risk factors affect women with germline pathogenic variants (PVs) in BRCA1/2, ATM, CHEK2, and PALB2. Using data from nearly 13,000 participants in the Women’s

Recently published: #BreastCancer Risk Modification in Women with Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2 and PALB2, by Allison W. Kurian et al. doi.org/10.1158/2767-9… Stanford Medicine Sid Yadav MD, FACP Pete Kraft #BreastCancerRisk #OpenAccess

I am so lucky to be in Berlin during the Victory Day celebrations—marking 80 years since the end of World War II. Being here, surrounded by history, is a powerful reminder of how far we’ve come and why it’s so important to remember the past. So we never repeat its mistakes.

Today at #ASCO25, I’ll be presenting findings from the VERITAC-2 study on vepdegestrant in ER+/HER2- metastatic #breastcancer, the most common subtype, demonstrating a 43% risk reduction in progression/death for ESR1-mutant patients. NEJM nejm.org/doi/abs/10.105…

Frank Sinicrope, MD of Mayo Clinic Comprehensive Cancer Center Mayo Clinic presenting results of ATOMIC trial at ASCO #asco25 #plenary. Proud of our colleague!

Starting in 25 minutes. I will be presenting the OS data based on germline PV carrier status among approximately 25,000 women with breast cancer in the CARRIERS study. Hall S103. #ASCO25

Honored to have presented 1 oral abstract and presented/co-authored 4 posters at #ASCO25 —an incredible experience representing the impactful research led by Mayo Clinic Comprehensive Cancer Center . Grateful to my collaborators for their partnership and support.

अमेरिकाको मेयो क्लिनिकका क्यान्सर विशेषज्ञ डा सिद्धार्थ यादवले अमेरिकन सोसाइटी अफ क्लिनिकल अन्कोलोजीको वार्षिक सम्मेलनमा स्तनक्यान्सर भएका महिलाको दीर्घकालीन स्वास्थ्य परिणाममा जेनेटिक म्यूटेसनले पार्नेप्रभाव वारे नयाँअध्ययन सार्वजनिक गरेका छन Sid Yadav MD, FACP nepalhealthpress.com/noncommunicabl…

In oncology, we don’t usually love overlapping Kaplan-Meier curves. Except that sometimes we really do. Thanks to NSABP-B51, countless pts will be spared the toxicity of nodal irradiation, and many will live free from a permanent lymph edema that would have impacted their lives.

A cheaper way to identify HRD positive tumors that might benefit from PARPi+Bev maintenance in ovarian cancer? In the PAOLA-1/ENGOT-ov25 trial (n=519), BRCA1/RAD51C methylation testing showed PFS & OS benefit with bevacizumab+olaparib maintenance. ✅ Identified ~85% of HRD+